Evidence map›Paper›PMID 40042766›Full record

ReviewMolecular biotechnology2026

Evolving Landscape of Emerging Virus Diagnosis: Challenges and Innovations.

Anoop Kumar, Supriya Saini, Anupkumar Anvikar, Neelima Mishra, Gauri Misra

Abstract readReview
PubMed Publisher
In one paragraph

Review in Molecular biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Anoop KumarNational Institute of Biologicals, A 32 Sector 62, Noida, Uttar Pradesh, 201309, India.
Supriya SainiNational Institute of Biologicals, A 32 Sector 62, Noida, Uttar Pradesh, 201309, India.
Anupkumar AnvikarNational Institute of Biologicals, A 32 Sector 62, Noida, Uttar Pradesh, 201309, India.
Neelima MishraNational Institute of Biologicals, A 32 Sector 62, Noida, Uttar Pradesh, 201309, India.
Gauri MisraNational Institute of Biologicals, A 32 Sector 62, Noida, Uttar Pradesh, 201309, India. gauri.misra@nib.gov.in.ORCID http://orcid.org/0000-0003-0759-4174

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Emerging and re-emerging viruses (like Spanish flu, SARS-CoV-2, etc.) have substantially impacted global public health since the early twentieth century. These outbreaks are unpredictable and novel viruses are difficult to understand due to emerging variations. Advanced virology and diagnostic technologies have revolutionized viral diagnostics, enabling accurate early identification and successful treatment and containment. Next-generation sequencing (NGS) technologies, such as metagenomics and whole-genome sequencing, have played a crucial role in the detection and monitoring of emerging viruses, such as SARS-CoV-2 and its variants. Advanced diagnostic methods, such as digital PCR, CRISPR-based tools, and serological techniques like ELISA, enhance viral detection's sensitivity, specificity, and speed. Research has shown that innovations such as lateral flow immunoassays, biosensors, and aptamers have the potential to significantly enhance diagnostic accuracy in various fields. The integration of AI in diagnostics aids researchers in understanding viral evolution and outbreak management, offering new avenues for rapid response. This review aims to examine the latest advancements in virus diagnosis technologies, identify unresolved accuracy and detection issues, and discuss emerging ideas that are transforming the future of viral diagnostics. It is important to improve early identification, rendering the system more cost-effective and adaptable to new viral threats.

Indexed as

Communicable Diseases, EmergingCOVID-19SARS-CoV-2Virus DiseasesBiosensing TechniquesHigh-Throughput Nucleotide SequencingHumansDigital PCREmerging virusesMolecular diagnosticsViral diagnosisViral pandemics

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.